Skip to Main Content

WASHINGTON — The drug industry is bracing for a deluge of drug pricing proposals from the soon-to-be Democratic House of Representatives. But it’s not worried about the controversial policies that have been blaring in TV ads and featured in stump speeches in recent months.

Democrats campaigned on a slate of sweeping drug pricing proposals, like allowing Medicare to negotiate directly with drug companies and creating a Senate-confirmed price-gouging enforcer. But those ideas are likely dead on arrival in the Senate, which remains in Republican control.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!